NEWS

Company news and the latest scientific findings

Apr 2024

ME THERAPEUTICS ANNOUNCES UPCOMING PARTICIPATION IN THE 2024 BLOOM BURTON & CO HEALTH CARE CONFERENCE AND INTERVIEW ON CSE TV

ME Therapeutics Holdings Inc. (METX:CSE), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of Immuno-Oncology,

BC, VANCOUVER

Apr 2024

ME THERAPEUTICS ANNOUNCES CLOSING OF NON-BROKERED PRIVATE PLACEMENT

ME Therapeutics Holdings Inc. (METX:CSE), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of Immuno-Oncology,

BC, VANCOUVER

Mar 2024

ME THERAPEUTICS ANNOUNCES NON-BROKERED PRIVATE PLACEMENT AND PROVIDES CORPORATE UPDATE

ME Therapeutics Holdings Inc. (METX:CSE), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of Immuno-Oncology,

BC, VANCOUVER

Jan 2024

ME THERAPEUTICS HOLDINGS INC. PROVIDES CORPORATE UPDATES

ME Therapeutics Holdings Inc. (METX:CSE), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of Immuno-Oncology,

BC, VANCOUVER

Dec 2023

ME THERAPEUTICS HOLDINGS INC. ANNOUCES LISTING ON THE FRANKFURT STOCK EXCHANGE (FSE) AND THE COMPLETION OF ITS REDESIGNED WEBSITE

ME Therapeutics Holdings Inc. (METX:CSE), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of Immuno-Oncology,

BC, VANCOUVER

Dec 2023

ME THERAPEUTICS HOLDINGS INC. Provides An Overview And Update On Current Research And Development Programs

ME Therapeutics Holdings Inc. (METX:CSE), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of Immuno-Oncology,

BC, VANCOUVER

Oct 2023

ME THERAPEUTICS HOLDINGS INC. Receives Funding Support For Preclinical Testing Of Prodrug Candidates

ME Therapeutics Holdings Inc. (CSE: METX) (the “Company” or “MET”), a preclinical stage biotechnology company working on novel cancer fighting drugs

BC, VANCOUVER

Oct 2023

ME THERAPEUTICS HOLDINGS INC. Announces Listing And Trading Of Its Common Shares On The Canadian Securities Exchange

ME Therapeutics Holdings Inc. (CSE: METX) (the “Company” or “MET”), a preclinical stage biotechnology company working on novel cancer fighting drugs

BC, VANCOUVER

Mar 2023

ME THERAPEUTICS INC. Publishes Research On The Role Of G-CSF In Breast And Colorectal Cancer In Cancer Research Communications

ME Therapeutics Inc., a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of Immuno-Oncology, is pleased

BC, VANCOUVER

Mar 2023

ME THERAPEUTICS INC. Announces The Grant Of A Chinese Patent On Their Lead G-CSF Antibody Candidate

ME Therapeutics Inc., a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of Immuno-Oncology, is pleased

Check out our profile on SEDAR+

BC, VANCOUVER

Apr 2024

ME THERAPEUTICS ANNOUNCES UPCOMING PARTICIPATION IN THE 2024 BLOOM BURTON & CO HEALTH CARE CONFERENCE AND INTERVIEW ON CSE TV

BC, VANCOUVER

Apr 2024

ME THERAPEUTICS HOLDINGS INC. ANNOUCES LISTING ON THE FRANKFURT STOCK EXCHANGE (FSE) AND THE COMPLETION OF ITS REDESIGNED WEBSITE

BC, VANCOUVER

Dec 2023

ME THERAPEUTICS INC. Publishes Research On The Role Of G-CSF In Breast And Colorectal Cancer In Cancer Research Communications

BC, VANCOUVER

Mar 2023

NEWS

Company news and the latest scientific findings

ME THERAPEUTICS ANNOUNCES UPCOMING PARTICIPATION IN THE 2024 BLOOM BURTON & CO HEALTH CARE CONFERENCE AND INTERVIEW ON CSE TV

ME THERAPEUTICS ANNOUNCES CLOSING OF NON-BROKERED PRIVATE PLACEMENT

ME THERAPEUTICS ANNOUNCES NON-BROKERED PRIVATE PLACEMENT AND PROVIDES CORPORATE UPDATE

ME THERAPEUTICS HOLDINGS INC. PROVIDES CORPORATE UPDATES

ME THERAPEUTICS HOLDINGS INC. ANNOUCES LISTING ON THE FRANKFURT STOCK EXCHANGE (FSE) AND THE COMPLETION OF ITS REDESIGNED WEBSITE

ME THERAPEUTICS HOLDINGS INC. Provides An Overview And Update On Current Research And Development Programs

ME THERAPEUTICS HOLDINGS INC. Receives Funding Support For Preclinical Testing Of Prodrug Candidates

ME THERAPEUTICS HOLDINGS INC. Announces Listing And Trading Of Its Common Shares On The Canadian Securities Exchange

ME THERAPEUTICS INC. Publishes Research On The Role Of G-CSF In Breast And Colorectal Cancer In Cancer Research Communications

ME THERAPEUTICS INC. Announces The Grant Of A Chinese Patent On Their Lead G-CSF Antibody Candidate

Check out our profile on SEDAR+

ME THERAPEUTICS ANNOUNCES UPCOMING PARTICIPATION IN THE 2024 BLOOM BURTON & CO HEALTH CARE CONFERENCE AND INTERVIEW ON CSE TV

ME THERAPEUTICS ANNOUNCES CLOSING OF NON-BROKERED PRIVATE PLACEMENT

ME THERAPEUTICS ANNOUNCES NON-BROKERED PRIVATE PLACEMENT AND PROVIDES CORPORATE UPDATE

ME THERAPEUTICS HOLDINGS INC. PROVIDES CORPORATE UPDATES

ME THERAPEUTICS HOLDINGS INC. ANNOUCES LISTING ON THE FRANKFURT STOCK EXCHANGE (FSE) AND THE COMPLETION OF ITS REDESIGNED WEBSITE

ME THERAPEUTICS HOLDINGS INC. Provides An Overview And Update On Current Research And Development Programs

ME THERAPEUTICS HOLDINGS INC. Receives Funding Support For Preclinical Testing Of Prodrug Candidates

ME THERAPEUTICS HOLDINGS INC. Announces Listing And Trading Of Its Common Shares On The Canadian Securities Exchange

ME THERAPEUTICS INC. Publishes Research On The Role Of G-CSF In Breast And Colorectal Cancer In Cancer Research Communications

ME THERAPEUTICS INC. Announces The Grant Of A Chinese Patent On Their Lead G-CSF Antibody Candidate

Keep up to date by subscribing to our mailing list

Links

Social

Get In Touch

© 2023 ME Therapeutics All Rights Reserved.